Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
AN2 Therapeutics, Inc. (ANTX) had Income from Continuous Operations of $-6.46M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.46M |
|
-- |
|
-- |
|
$7.22M |
|
$-7.22M |
|
$0.75M |
|
$-6.46M |
|
$-6.46M |
|
$-6.46M |
|
|
Income from Continuous Operations |
$-6.46M |
$-6.46M |
|
$-6.46M |
|
$-7.22M |
|
$-7.51M |
|
30.17M |
|
30.17M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$67.52M |
|
-- |
|
$8.30M |
|
$75.83M |
|
$6.98M |
|
-- |
|
-- |
|
$6.98M |
|
$68.84M |
|
$68.84M |
|
$68.84M |
|
27.38M |
|
| Cash Flow Statement Financials | |
$-18.22M |
|
$15.03M |
|
$0.07M |
|
$21.35M |
|
$18.22M |
|
$-3.13M |
|
$4.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.39% |
|
-9.39% |
|
-8.52% |
|
-9.39% |
|
$2.51 |
|
$-0.60 |
|
$-0.60 |
|